Journal ArticleOPEN ACCESS

Upadacitinib for the treatment of rheumatoid arthritis

  • Chaplin S
Prescriber (2020) 31(3) 32-34
DOI: 10.1002/psb.1832
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Upadacitinib (Rinvoq) is a new janus kinase inhibitor licensed for the treatment of rheumatoid arthritis in adults. This article discusses its indications, clinical trial efficacy and adverse effects.

Cite

CITATION STYLE

APA

Chaplin, S. (2020). Upadacitinib for the treatment of rheumatoid arthritis. Prescriber, 31(3), 32–34. https://doi.org/10.1002/psb.1832

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free